The purpose of this study is to provide prospective evidence that the use of
Magseed/Sentimag in marking axillary lymph nodes and guiding surgical localization in
patients with breast cancer following neo-adjuvant chemotherapy (NAC) is effective.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03796559.
Locations matching your search criteria
United States
Texas
Houston
M D Anderson Cancer CenterStatus: Active
Contact: Christan Ross
Phone: 713-792-6550
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer CenterStatus: Active
Name Not Available
This is a post-market, prospective, open-label, single arm study of Magseed and Sentimag
in patients with breast cancer with biopsy-proven axillary node metastases who had a clip
placed to mark the metastatic node and are having that clipped node selectively removed
at surgery following neo-adjuvant chemotherapy (NAC). Subjects will have the Magseed
placed to mark axillary lymph nodes with biopsy-proven metastasis under ultrasound
guidance before initiating NAC. After completion of NAC, the Magseed will be localized
using the Sentimag system during surgery and removed with the targeted lymph node.
Trial PhaseNo phase specified
Trial Typetreatment
Lead OrganizationEndomagnetics Inc
